Exact Mass: 1056.5657364

PIP(20:2(11Z,14Z)/6 keto-PGF1alpha)

C49H86O20P2 (1056.5187415999999)

PIP(20:2(11Z,14Z)/6 keto-PGF1alpha) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(20:2(11Z,14Z)/6 keto-PGF1alpha), in particular, consists of one chain of 11Z,14Z-eicosadienoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

PIP(6 keto-PGF1alpha/20:2(11Z,14Z))

C49H86O20P2 (1056.5187415999999)

PIP(6 keto-PGF1alpha/20:2(11Z,14Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(6 keto-PGF1alpha/20:2(11Z,14Z)), in particular, consists of one chain of 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of 11Z,14Z-eicosadienoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

PIP(20:2(11Z,14Z)/TXB2)

C49H86O20P2 (1056.5187415999999)

PIP(20:2(11Z,14Z)/TXB2) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(20:2(11Z,14Z)/TXB2), in particular, consists of one chain of 11Z,14Z-eicosadienoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

PIP(TXB2/20:2(11Z,14Z))

C49H86O20P2 (1056.5187415999999)

PIP(TXB2/20:2(11Z,14Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(TXB2/20:2(11Z,14Z)), in particular, consists of one chain of Thromboxane B2 at the C-1 position and one chain of 11Z,14Z-eicosadienoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

Iturin A-3

C49H76N12O14 (1056.5603676)

Sapimukoside F

C54H88O20 (1056.5868648)

Iturin A-5

C49H76N12O14 (1056.5603676)

Verbesinoside E

C56H80O19 (1056.5293530000001)

Latifoloside K

C53H84O21 (1056.5504814)

3-[6,12,22-tris(2-amino-2-oxoethyl)-19-(hydroxymethyl)-9-[(4-hydroxyphenyl)methyl]-16-(10-methylundecyl)-2,5,8,11,14,18,21,24-octaoxo-1,4,7,10,13,17,20,23-octazabicyclo[23.3.0]octacosan-3-yl]propanamide

C49H76N12O14 (1056.5603676)

Sapimukoside I

C54H88O20 (1056.5868648)

tyrianthinic acid I

C50H88O23 (1056.5716098)

(3beta,21beta,22alpha)-3-(3-O-angeloyl-beta-D-glucopyranosyloxy)-21,22-dihydroxy-28-beta-sophorosyloxy-16-oxoolean-12-ene|terminaliaside A

C53H84O21 (1056.5504814)

C53H84O21

C53H84O21 (1056.5504814)

2,3-dihydroxyCTX3C

C57H84O18 (1056.5657364)

C57H84O18

C57H84O18 (1056.5657364)

micropeptin DR1056

C54H72N8O14 (1056.5167732)

alternoside XIV|chichipegenin 22-O-tigloyl-3-O-beta-D-glucopyranosyl(1->3)-beta-D-glucuronopyranosyl-28-O-beta-D-glucopyranoside

C53H84O21 (1056.5504814)

11(S)-convolvulinolic acid 11-O-beta-D-glucopyranosyl-(1->3)-O-[4-O-2S-methylbutyryl-alpha-L-rhamnopyranosyl-(1->4)-]-O-alpha-L-rhamnopyranosyl-(1->4)-O-alpha-L-rhamnopyranosyl-(1->2)-beta-D-fucopyranoside-1,3-ester|quamoclin V

C49H84O24 (1056.5352264)

26-O-beta-D-glucopyranosyl-22alpha-methoxyfurosta-5,25(27)-diene-1beta,3beta,26-triol 1-O-alpha-L-rhamnopyranosyl-(1->2)-3-acetyl-4-[(2S,3S )-2-hydroxy-3-methylpentanoyl]-alpha-L-arabinopyranoside

C53H84O21 (1056.5504814)

quamoclin VI

C49H84O24 (1056.5352264)

stemmoside C

C54H88O20 (1056.5868648)

3beta,16alpha-dihydroxy-14Hbeta,17Hbeta-pregn-5-en-15-one-3-O-beta-D-glucopyranosyl-(1->4)-beta-D-oleandropyranosyl-(1->4)-beta-D-canaropyranosyl-(1->4)-beta-D-cymaropyranosyl-(1->4)-beta-D-cymaropyranoside|stemmoside G

C54H88O20 (1056.5868648)

cyclo(D-Pro-L-Gln-L-Asn-L-Ser-D-Asn-D-Tyr-D-Asn-D-beta-aminoanteisopentadecanoic acid)|maribasin B

C49H76N12O14 (1056.5603676)

hoyacarnoside I

C53H84O21 (1056.5504814)

3-O-beta-D-galactopyranosyl(1->2)[alpha-L-rhamnopyranosyl(1->3)] beta-D-glucuronopyranosyl 28-O-angeloyl-A1-barrigenol

C53H84O21 (1056.5504814)

3-O-beta-D-glucopyranosyl-(1->2)-alpha-L-rhamnopyranosyl-(1->4)-beta-D-glucuronopyranosyl-22-O-beta,beta-dimethylacryloyl-A1-barrigenol

C53H84O21 (1056.5504814)

cyclo(D-Pro-L-Gln-L-Asn-L-Ser-D-Asn-D-Tyr-D-Asn-D-beta-aminoisopentadecanoic acid)|maribasin A

C49H76N12O14 (1056.5603676)

3-O-beta-D-glucopyranosyl(1->2)[alpha-L-rhamnopyranosyl(1->3)] beta-D-glucuronopyranosyl 22-O-angeloyl-A1-barrigenol

C53H84O21 (1056.5504814)

1-O-[(3beta)-3-{[6-deoxy-3-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-galactopyranosyl]oxy}-28-oxoolean-12-en-28-yl]-4-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranose|3-O-(alpha-L-rhamnopyranosyl(1->3)-beta-D-fucopyranosyl)-28-O-[alpha-L-rhamnopyranosyl(1->4)-beta-D-glucopyranosyl]oleanolic acid

C54H88O20 (1056.5868648)

3-[6,12,22-tris(2-amino-2-oxoethyl)-19-(hydroxymethyl)-9-[(4-hydroxyphenyl)methyl]-16-(10-methylundecyl)-2,5,8,11,14,18,21,24-octaoxo-1,4,7,10,13,17,20,23-octazabicyclo[23.3.0]octacosan-3-yl]propanamide)

C49H76N12O14 (1056.5603676)

Iturin A-4

C49H76N12O14 (1056.5603676)

PIP(20:2(11Z,14Z)/TXB2)

C49H86O20P2 (1056.5187415999999)

PIP(TXB2/20:2(11Z,14Z))

C49H86O20P2 (1056.5187415999999)

PIP(20:2(11Z,14Z)/6 keto-PGF1alpha)

C49H86O20P2 (1056.5187415999999)

PIP(6 keto-PGF1alpha/20:2(11Z,14Z))

C49H86O20P2 (1056.5187415999999)

[3-[[3-[[3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropyl] (15Z,18Z)-tetracosa-15,18-dienoate

C55H94O15P2 (1056.6067633999999)

[3-[[3-[[3-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropyl] (6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoate

C55H94O15P2 (1056.6067633999999)

[3-[[3-[[3-[(7Z,10Z,13Z,16Z)-docosa-7,10,13,16-tetraenoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropyl] (9Z,12Z,15Z,18Z)-tetracosa-9,12,15,18-tetraenoate

C55H94O15P2 (1056.6067633999999)

[3-[[3-[[3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropyl] (9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoate

C55H94O15P2 (1056.6067633999999)

[3-[[3-[[3-[(E)-docos-13-enoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropyl] (3Z,6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-3,6,9,12,15,18,21-heptaenoate

C55H94O15P2 (1056.6067633999999)

[3-[[3-[[3-[(7E,9E,11E,13E,15Z,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropyl] (E)-tetracos-15-enoate

C55H94O15P2 (1056.6067633999999)

[3-[[3-[[3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxy-2-hydroxypropyl] (12Z,15Z,18Z)-tetracosa-12,15,18-trienoate

C55H94O15P2 (1056.6067633999999)

MLCL 45:8

C54H90O16P2 (1056.57038)

PIM1 39:7

C54H89O18P (1056.5786224)

MART-1 (26-35) (human) (TFA)

C44H75F3N10O16 (1056.5314346)

MART-1 (26-35) (human) TFA is amino acid residue 26 to 35 of MART-1 protein.

(11r)-11-{[(2r,3r,4s,5s,6r)-3-{[(2s,3r,4s,5r,6r)-3-{[(2s,3r,4r,5r,6s)-5-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-5-{[(2s,3s)-3-hydroxy-2-methylbutanoyl]oxy}-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyl-3-{[(2s)-2-methylbutanoyl]oxy}oxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5-dihydroxy-6-methyloxan-2-yl]oxy}hexadecanoic acid

C50H88O23 (1056.5716098)

(2s,3r,4r,5r,6s)-2-{[(2r,3r,4s,5r,6r)-2-{[(1s,3as,5ar,7s,9ar,9br,11as)-1-[(2s,3s,5r)-2-methoxy-5-(2-methylprop-1-en-1-yl)oxolan-3-yl]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-{[(2s,3r,4r,5s,6s)-3,5-dihydroxy-6-methyl-4-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}-6-methyloxane-3,4,5-triol

C54H88O20 (1056.5868648)

2-{[3-({3,5-dihydroxy-6-methyl-4-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl}oxy)-2-({1-[2-ethoxy-5-(2-methylprop-1-en-1-yl)oxolan-3-yl]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl}oxy)-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}oxane-3,4,5-triol

C54H88O20 (1056.5868648)

3-[(3r,6s,9r,13s,16r,19r,22s,27as)-1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-(10-methylundecyl)-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

C49H76N12O14 (1056.5603676)

2-{[8a-({[4,5-dihydroxy-6-(hydroxymethyl)-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}methyl)-9,10-dihydroxy-4,4,6a,6b,11,11,14b-heptamethyl-8-oxo-2,3,4a,5,6,7,9,10,12,12a,14,14a-dodecahydro-1h-picen-3-yl]oxy}-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl 2-methylbut-2-enoate

C53H84O21 (1056.5504814)

3-[1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-(10-methylundecyl)-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

C49H76N12O14 (1056.5603676)

3-[(3r,6s,9r,13s,16r,19r,22s,27as)-1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-[(9s)-9-methylundecyl]-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

C49H76N12O14 (1056.5603676)

(11r)-11-{[(2r,3r,4s,5s,6r)-3-{[(2s,3r,4s,5s,6r)-3-{[(2s,3r,4r,5r,6s)-5-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-5-[(3-hydroxy-2-methylbutanoyl)oxy]-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyl-3-[(2-methylbutanoyl)oxy]oxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4,5-dihydroxy-6-methyloxan-2-yl]oxy}hexadecanoic acid

C50H88O23 (1056.5716098)

(1r,3ar,3bs,7s,9ar,9br,11r,11as)-1-acetyl-3a,3b-dihydroxy-7-{[(2r,4s,5r,6r)-5-{[(2s,4s,5s,6r)-4-hydroxy-5-{[(2s,4s,5r,6r)-5-{[(2s,4s,5r,6r)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-4-methoxy-6-methyloxan-2-yl]oxy}-9a,11a-dimethyl-1h,2h,3h,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-11-yl (2e)-3-phenylprop-2-enoate

C57H84O18 (1056.5657364)

3-[(3r,7r,10r,13r,16s,19s,22s,27ar)-1,5,8,11,14,17,20-heptahydroxy-7,13,19-tris(c-hydroxycarbonimidoylmethyl)-16-(hydroxymethyl)-10-[(4-hydroxyphenyl)methyl]-3-[(9s)-9-methylundecyl]-23-oxo-3h,4h,7h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-c]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

C49H76N12O14 (1056.5603676)

(2s)-n-[(2s,5s,8s,11r,12s,15s,18s,21r)-5-benzyl-8-[(2s)-butan-2-yl]-6,13,16,21-tetrahydroxy-15-[(4-hydroxyphenyl)methyl]-4,11-dimethyl-2-(2-methylpropyl)-3,9,22-trioxo-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl]-2-{[(2r)-1,2-dihydroxy-3-(4-hydroxyphenyl)propylidene]amino}pentanediimidic acid

C54H72N8O14 (1056.5167732)

3-[1,5,8,11,14,17,20-heptahydroxy-7,13,19-tris(c-hydroxycarbonimidoylmethyl)-16-(hydroxymethyl)-10-[(4-hydroxyphenyl)methyl]-3-(9-methylundecyl)-23-oxo-3h,4h,7h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-c]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

C49H76N12O14 (1056.5603676)

(2s,3r,4s,5s)-2-{[(2r,3r,4s,5r,6r)-2-{[(1s,3as,5ar,7s,9ar,9br,11as)-1-[(2s,3s,5r)-2-ethoxy-5-(2-methylprop-1-en-1-yl)oxolan-3-yl]-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3-{[(2s,3r,4r,5s,6s)-3,5-dihydroxy-6-methyl-4-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy}oxane-3,4,5-triol

C54H88O20 (1056.5868648)

3-[(3r,6s,9r,13s,16r,19r,22s,27as)-1,4,7,11,14,17,20-heptahydroxy-3,13,19-tris(c-hydroxycarbonimidoylmethyl)-6-(hydroxymethyl)-16-[(4-hydroxyphenyl)methyl]-9-[(9r)-9-methylundecyl]-23-oxo-3h,6h,9h,10h,13h,16h,19h,22h,25h,26h,27h,27ah-pyrrolo[2,1-i]1,4,7,10,13,16,19,22-octaazacyclopentacosan-22-yl]propanimidic acid

C49H76N12O14 (1056.5603676)